Introduction
============

Osteoarthritis (OA) is a well-established form of rheumatic disease, denoted by the degeneration of articular cartilage, synovial inflammation and changes in the subchondral bone. The pathophysiology of OA is still unclear, but it is known that the degradation of cartilage is mainly due to the prevalence of catabolic processes as well as reduced cartilage cellularity with aging ([@B19]). Currently, regenerative therapies for OA are scarce and are not effective inrelation to the gradual degeneration of joint tissues within a clinical context and mainly focuses on reducing pain and improving articular function. Therefore, non-steroidal anti-inflammatory drugs, infiltrative therapies and the total joint replacement represent the main treatments in clinical practice ([@B7]). However, considering that OA is characterized by degeneration and failure in repairing cartilage due to lack of blood supply, it is then, relevant to consider mesenchymal stem cells (MCs) in OA management ([@B6]).

Friedenstein first defined MSCs, illustrating a subpopulation of cells that contained osteogenic potential within the bone marrow stromal ([@B15]). Nowadays, MSCs are commonly isolated from adipose tissue, the synovium, periosteum, dermis, bone trabeculae, infrapatellar fat pad and muscle with similar phenotypes but differing proliferative and differentiative abilities ([@B17]). MSCs have undoubtedly a critical role in homeostasis and tissue repair with the ability to differentiate into all connective lineages of tissue depending on the stimuli provided ([@B21]).

Adipose-derived MSCs (ASCs) from lipoaspirates are an effective cell source due to their abundance accessibility and ability to differentiate in several cellular lineage.

Some studies demonstrated for the first time that ASCs positive for pericytic markers, including NG2, when loaded on a crosslinked hyaluronic acid scaffold and grafted into nude mice was able to differentiate in muscle tissue ([@B10]). Another study reveal that that hyaluronic acid potentiate ASCs differentiation of resident fat cell of the face preserving both morphology and viability ([@B25]). It was also largely used in breast lipofilling even caution should be paid, because it has been demonstrated that hASCs may enenced tumor angiogenesis ([@B22]).

The increasing interest about using ASCs in osteoarticular disorders are enforced because different studies revealed that ASCs had potentiality to differentiate into bone tissue ([@B18]) and into cartilage ([@B30]). Current research has favorably described different uses of these cells for infiltration or for scaffold implants employing different biomaterials, growth factor, hyaluronic acid or platelet rich-plasma ([@B13]). The most effective strategy has, indeed yet to be defined and will not be discussed herein. ASCs are isolated by the aqueous fraction derived from the digestion of lipoaspirates. This aqueous fraction constituted by ASCs is known as the stromal vascular fraction (SVF) containing endothelial precursor cells (EPCs), endothelial cells (ECs), macrophages, smooth muscle cells, lymphocytes, pericytes, and pre-adipocytes ([@B5]). The clinical application of ASCs and SVF is steadily increasing along with a need for steadfast information regarding adequacy and cost of automated and manual appliances to isolate SVF from adipose tissue. Two techniques have currently been proposed: enzymatic and mechanical methods with evidence of a more efficient enzymatic procedure in the separation of SVF which disarrays the extracellular matrix (ECM) and binds adipocytes from other cells ([@B30]). However, in view of the Good Manufacturing Practice regulations regarding "cell manufacturing" ([@B24]; [@B2]), the extensive use and manipulation of stem cells are not applicable according to the European Parliament and Council (EC regulation no. 1394/2007) in relation to the minimal manipulation ([@B9]). An alternative mechanical procedure as compared to the enzymatic method is therefore imperative to isolate SVF ([@B3]). In this study, we analyze the SVF harvested from subcutaneous abdominal fat from five patients derived from two different mechanical methods and the most common enzymatic method. In particular, we focus on SVF isolated from the various methods, cell viability (at 0 and after 72 h) and the expression in clusters of differentiation (CD) and the ability to differentiate in adipocytic, chondrocytic, osteocytic lineage.

Materials and Methods {#s1}
=====================

Patients and Tissues
--------------------

Between February 2018 and June 2018, five patients (three women and two men) underwent liposuction and lipofilling procedures for esthetic purposes with ages ranging between 45 to 65 years (mean 54.3 ± 10). Inclusion and exclusion criteria are summarized in [Table 1](#T1){ref-type="table"}. Patients provided consent before surgery, in line with the ethical guidelines set by the review board for human studies of the "Ospedali Riuniti" Hospital, Ancona, Italy (Micro-adipose graft_01, 18 May 2017). The liposuction procedure was performed according to the BEAULI protocol, described by [@B28]. A pulsating water jet was used for infiltration and simultaneous aspiration. The infiltration ranges were set to 1--3 from 90 mL/min ± 15% to 130 mL/min ± 15%. Klein's tumescence solution was pre-heated at 37--38°C. The sharp-tipped cannulas measured 22 mm in external diameter. We proceeded with aspiration promptly after the first infiltration. For each patient, we collected 30 mL of lipoaspirate tissue equally divided (10 mL) for each procedure.

###### 

We reported the exclusion and inclusion criteria of patients' characteristics.

  Inclusion criteria                           Exclusion criteria
  -------------------------------------------- -----------------------------------------
  Age \< 65 aa                                 Diabetes mellitus type I and II
  Body Mass Index \>25 kg/m^2^ \< 30 kg/m^2^   Cardiovascular or neurologic disorders
                                               Patients in chronic drug therapy
                                               Smoke
                                               Previous abdominal surgery (laparotomy)
                                               

Enzymatic Isolation of SVF
--------------------------

One portion of lipoaspirates from each patient was digested with collagenase according to the preceding protocol ([@B13]). The lipoaspirates were briefly digested at 37°C in DMEM with 0.25% weight per volume percent (w/v) collagenase type I (Sigma-Aldrich, St. Louis, MO, United States) and 1% fetal bovine serum (FBS) for 180 min at 37°C. Following digestion, we filtered the resulting suspension through a sterile 100 μm nylon mesh to remove undigested parts and centrifuged the remaining suspension at 1200 *g* for 10 min, to extract a high-density pellet, composed of the SVF. The SVF thus obtained was re-suspended in 10 mL DMEM supplemented with 10% Foetal Bovine Serum (FBS) and 1% penicillin-streptomycin (all Gibco^®^, Thermo Fisher Scientific, Paisley, United Kingdom), seeded in 96-well plates (100 μl/well) and were stored in a humidified incubator at 37°C with 5% CO~2~ to assess viability. The remaining part was seeded in 60 mm petri dishes and used for flow cytometric characterization.

Non-enzymatic Methods
---------------------

In this study we evaluated two mechanical technologies: Rigenera^®^ (Human Brain Wave HBW, Turin, Italy), Lipogems^®^ ortho kit (Lipogems International SpA, Milan, Italy). Two portions of the harvested fat of each patient was inserted into each device, according to each manufacturer's instructions ([@B4]; [@B13]; [@B11]). The SVF obtained with each method, as for the SVF obtained by enzymatic digestion, was brought to the volume of 10 mL with DMEM supplemented with 10% FBS and 1% penicillin--streptomycin (all Gibco^®^, Thermo Fisher Scientific, Paisley, United Kingdom). Cells was seeded in 96-well plates (100 μl/well) and were stored in a humidified incubator at 37°C with 5% CO~2~ to assess viability. The remaining part was seeded in 60 mm petri dishes and used for flow cytometric characterization.

Evaluation of Cell Viability
----------------------------

The viability of cells was evaluated through PrestoBlue test (Life Technologies Corporation, OR, United States) following each manufacturer's protocol. Hundred microliters of cell suspension obtained from each processing method was seeded in a 96-well micro titer plate. Subsequently, 10 μl of PrestoBlue reagent was added. The cell viability alterations were analyzed via absorbance spectroscopy and we reported the absorbance 570 nm after 10 min incubation at 37°C through multi-mode microplate readers (Tecan Trading AG, Switzerland). Cell viability was evaluated at T0 and T (72h) and was performed in triplicate in every sample for each method.

Flow Cytometry Analysis
-----------------------

At confluence, cells derived from each technique were detached with trypsin-EDTA (Gibco^®^, Thermo Fisher Scientific, Paisley, United Kingdom). Cells were washed with PBS, about 2 × 10^5^ were placed in 5 mL round-bottom polystyrene tubes and then stained for 30 min at 4°C using fluorescent conjugated antibodies. The following monoclonal antibodies were investigated: anti-CD34 PE and anti-CD45 PE (both Diaclone, Besançon, France), anti-CD90 FITC (StemCell Technologies, Vancouver, BC, Canada), anti-CD73 PE (BD Biosciences Pharmingen, San Jose, CA, United States), anti-CD235a (Miltenyi Biotec, Germany) and anti-CD31 1:50 (Dako Agilent, Santa Clara, CA, United States). After 45 min, cells were washed and then stained with goat anti-mouse IgG FITC secondary antibody 1:500 (Invitrogen, Thermo Fisher Scientific). After immunostaining, the cells were rinsed in PBS, re-suspended in 0.5 mL of FACSFlow and examined by FACSCalibur flow cytometry system (Becton Dickinson, CA, United States). We used isotypic mouse IgG1 as control for FITC and PE-coupled antibodies, and secondary antibody only for indirect immunostaining. Data were collected and analyzed via CellQuest software (BD Biosciences, San Jose, CA, United States).

Differentiation
---------------

One sample was chosen randomly and was divided in three aliquote to perform phenotypical differentiation of enzymatic and mechanical processed SVF. For each type of treatment, the material was divided as follows: two thirds used for chondrogenic differentiation and a third for adipogenic and osteogenic differentiation.

Cells were cultured 10 mL DMEM supplemented with 10% Foetal Bovine Serum (FBS) and 1% penicillin-streptomycin (all Gibco^®^, Thermo Fisher Scientific, Paisley, United Kingdom), until confluency and medium was then substituted. The StemPro^®^ Chondrogenesis Differentiation Kit, StemPro^®^ Adipogenesis Differentiation Kit, and StemPro^®^ Osteogenesis Differentiation Kit, were used (all Gibco^®^, Thermo Fisher Scientific, Paisley, United Kingdom). The medium was changed twice a week. For osteogenic and adipogenic differentiation we used 35 mm petri. Indeed, for chondrogenic differentiation 15 mL centrifuge tubes were used, according to our experience.

After 14 days the cells obtained, cultivated in osteogenic medium were fixed with 4% formaldehyde and stained for ALP (alkaline phosphatase). After 21 days the cells obtained, cultivated in osteogenic medium were fixed with 4% formaldehyde and stained with Von Kossa and Alizarin red to highlight mineral deposition. The cells cultivated in medium with adipogenic medium were fixed in methanol and stained with Oil red O to highlight lipid droplets.

After 28 days the pellets formed in the centrifuge tubes with chondrogenic medium were fixed with 4% formaldehyde and processed for paraffin embedding. Five micrometers sections were stained with Safranin O and Alcian blue pH1 to highlight the presence of sulfurated acid proteoglycans. The Alcian blue pH 1 solution was purchased by Bio-Optica (Milan, Italy), the other staining solutions were prepared in the laboratory with Sigma-Aldrich products (Milan, Italy).

Statistical Analysis
--------------------

Population characteristics were defined using a mean ± standard deviation or median and range for the continuous variables and percentages related to the categorical variables. Data were assessed for normal distribution using the Kolmogorov--Smirnov test. Statistical significance was set at *p* \< 0.001. We used the Paired *t*-test to compare the continuous variables between the two groups and the result was considered statistically significant when *p* \< 0.005.

Results
=======

Cell Viability Assay
--------------------

Cell viability at T0 and T72h for each method is summarized in [Figure 1](#F1){ref-type="fig"}. We reported the average cell viability obtained from each method. The cell count was statistically higher at T0 for enzymatic technique of isolation in relation to the other mechanical methods (Collagenase: 28634^∗^, Lipogems^®^:13782 Rigenera^®^:13262). Moreover, at T72h cell viability was statistically lower in the Collagenase method only compared to T0 (19797), while the difference was statistically insignificant in the other group (Lipogems^®^:11950, Rigenera^®^:12932).

![Cell viability values (average of the samples) at T0 and T72h. Data marked with ^∗^ are statistically significant. Cell viability of SVF obtained by collagenase was significantly higher than those of mechanical methods (^∗^). However, the enzymatic procedure has been the only methods characterized by a significant decrease in cell viability at T72h^∗∗^. Cell medium was changed twice weekly in DMEM supplemented with 10% Foetal Bovine Serum (FBS) and 1% penicillin-streptomycin (all Gibco^®^, Thermo Fisher Scientific, Paisley, United Kingdom), seeded in 96-well plates (100 μl/well) and were stored in a humidified incubator at 37°C with 5% CO~2~ to assess viability.](fcell-07-00088-g001){#F1}

Cluster of Differentiation Analysis
-----------------------------------

Cytofluorimetric analysis of one sample processed by the enzymatic method and mechanical methods is reported below. Non-overlapping curves indicated positive staining, and overlapping curves indicated a negative value ([Figure 2](#F2){ref-type="fig"}). The percentage of staining CD markers are reported for each method (as an average of samples) in [Figure 3](#F3){ref-type="fig"}. Data were considered positive or negative according to Cell Quest software for statistical analysis and D/s(n) value.

![CD expression marker of one sample chosen randomly, showed as exemplification. In the first column the enzymatic technique reveals CD90, 73, 235a+, and CD45, 34, 31--. For the mechanical techniques, in the second Lipogems system CD90, 73, 235a, 45, 31+, and CD34--. Rigenera system in the last column CD90+, 73--, 235a+, and CD45--, 34--, 31+.](fcell-07-00088-g002){#F2}

![Percentage of staining CD cell (as average of the samples) for each method and technique analyzed. Collagenase: CD90 36% (+), CD73 15% (--), CD235a 59% (+), CD45 4% (--) CD34 5% (--) CD31 14% (--). Lipogems: CD90 31% (+), CD73 38% (+), CD235a 61% (+), CD45 28% (+) CD34 4% (--) CD31 42% (+). Rigenera: CD90 32% (+), CD73 8% (--), CD235a 61% (+), CD45 6% (--) CD34 5% (--) CD31 21% (+).](fcell-07-00088-g003){#F3}

Phenotypic Differentiation
--------------------------

After 14 days the cells obtained through Collagenase cultivated in osteogenic medium were stained for ALP (alkaline phosphatase). There were no adherent cells in petri dishes with Rigenera^®^ and Lipogems^®^ treatment.

After 21 days the cells obtained through Collagenase, cultivated in osteogenic medium were stained with Von Kossa and Alizarin red to highlight mineral deposition. There were no adherent cells in petri dishes with Rigenera^®^ and Lipogems^®^ treatment.

The cells obtained from the treatment with collagenase are cultivated in medium with adipogenic medium. There were no adherent cells in petri dishes with Lipogems^®^, and Rigenera^®^ treatment.

After 28 days the pellets formed in the centrifuge tubes with chondrogenic medium for Collagenase and Rigenera^®^ were fixed. Lipogems^®^, did not show in our opinion capability of differentiation. Rigenera shows the ability to differentiate in chondrocytic lineage ([Figure 4](#F4){ref-type="fig"}). Osteocytic, adipocytic, and chondrocytic differentiation was achieved only in enzymatic technique.

![Image showing panel **(A)** cells, obtained from collagenase digestion, in adipogenic medium, exhibiting the morphology of multi-vacuolar adipocytes (arrows; Scale bar: 200 μm); **(B)** cells, obtained from collagenase digestion, in osteogenic medium. Formation of mineralized matrix was detected by Von Kossa staining (arrows; Scale bar: 1 mm); **(C)** cells, obtained from collagenase digestion, in chondrogenic medium demonstrated by Alcian Blu staining; **(D)** cells, obtained from Rigenera digestion, in chondrogenic medium demonstrated by Alcian Blu staining.](fcell-07-00088-g004){#F4}

Discussion
==========

To date, autologous adipose SVF injection represents a promising, minimally invasive, non-surgical alternative in the field of orthopedics for the treatment of musculoskeletal disorders. Although various pre-clinical and clinical studies have been conducted to establish the potential role of ASCs and SVF to treat OA and/or cartilage lesions, a unanimous conclusion is still lacking due to inadequate standardization ([@B5]). Enzymatic methods produce cell populations considered "more than minimally manipulated," by the Food and Drug Administration and thus strictly regulated as a therapy. For these reasons, non-enzymatic methods were defined as "minimally manipulated" and were developed to circumvent the extensive regulations ([@B24]; [@B2]; [@B9]). According to our findings, collagenase-based digestion seemed to be more effective in terms of cell viability at T0 and T72h compared to mechanical techniques. As reported in literature ([@B8]) non-enzymatic methods revealed lower cell viability compared to enzymatic methods. However, differences between T0 and T72h in cell viability, were significantly lower in the enzymatic technique only, compared to other groups, in which an almost steady state of viability was maintained. No difference in cell viability between mechanical methods in both time points was reported.

Our study is inconclusive regarding the characterization of cluster differentiation. It is noteworthy that SVF comprises various cells such as macrophages, numerous blood cells, pericytes, fibroblasts, smooth muscle cells, vascular endothelial progenitors and ASCs. ASCs are known to be positive for classical MSC markers such as CD34, CD73, and CD90 but are not so for the pan-leucopoietic lineage marker CD45. In addition, progenitors of hematopoietic and endothelial lineage are expressed in CD34 whereas endothelial cells are positive for CD31 ([@B5]). CD235a is unexpressed in lymphoid or granulocytic progenitor cells and thus an efficient marker to detect the erythroid cell lineage. The composition of the cell populations retrieved via enzymatic methods are known to contain a higher frequency of peripheral blood. As regards the ASCs, we reported a strong positivity of CD90 and CD73, but a negativity of CD34. Recent investigations indicate that CD34 is expressed in tissue-resident MSCs, and its negativity is a consequence of cell culturing ([@B16]). On the other hand, [@B12] stated that ASCs were positive for MSC markers CD90, CD105, and CD73, and negative for CD45, CD11b, HLA-DR, CD34, and CD19 according to the international criteria which defines multipotent MSCs. For these reasons, we hypothesize that ASCs are present in SVF albeit at a substantially lower rate than in red blood cells.

Cluster differentiation expression in Collagenase technique showed the expression of CD90, CD235a and negativity for CD34, CD45, CD73, and CD31. Negativity for CD73 is borderline. CD expression in the mechanical methods Rigenera^®^ suggested that the SVF obtained was characterized by a substantial proportion of red blood and endothelial cells. Indeed, they expressed CD31, CD90 with a negativity for CD34, CD45, CD73 ([@B1]). Concerning Lipogems^®^, we observed a strong positivity for CD235a, CD31, CD90, CD73, CD45 with a negativity of CD34. Our studies revealed a collection of a significant amount of red blood cells. Furthermore, as stated above, the positivity of CD73 and CD90 suggests the presence of ASCs. The main limitations of our study were the small patient population and the extensive amount of SVF harvested from each method which included a substantial proportion of red blood cells. It should be noted that most of the techniques described in literature to obtain SVF are regulated by centrifugation, filtration and rinsing to avoid red blood cell contamination. We specifically did not undergo these procedures to analyze the entire SVF obtained from devices that may be used as infiltrative therapy for the treatment of OA in a single-step procedure ([@B23]).

Enzymatic methods have shown to be much more effective in terms of SVF cell recovery. Enzymatic methods employ proteolytic enzymes to disrupt the extracellular matrix which holds adipose tissue together. Collagenase-based enzymatic methods have reported nucleated cell yields much higher than mechanical methods. Furthermore, the composition of the cell population recovered by mechanical methods has a greater frequency of peripheral blood mononuclear cells with lower frequency of progenitor cells. While enzymatic methods yield consistently higher progenitor cells, non-enzymatic methods are not without merit. The differences resulting in the yields using mechanical and enzymatic methods can be partially attributed to the physical location of SVF cells in adipose tissue in perivascular space (niche). Mechanical methods of SVF isolation do not afford the same release of cells from the perivascular spaces because the disruption of the extracellular matrix is significantly reduced compared to enzymatic methods. As a result, the composition of the SVF resulting from mechanical isolations tends to be deficient in CD34 expression, with longer culture times. This issue is reflected much on the ability to differentiate into typical lineage. Only enzymatic technique showed good differentiation at proper time, instead we did not obtain differentiation from both mechanical devices, exception from ability to chondrocytic differentiation for Rigenera^®^. We explain this for the slower growth and the difficulty in reaching confluence but also because mechanical devices are able to select pre-commitment cells, that have not potentiality to differentiate in all cellular lineage of mesodermal leaflet, may because they have already lost CD34 positivity.

Literature has extensively reported SVF as a promising tool in orthopedics ([@B26]; [@B14]; [@B29]) but it is noteworthy to consider in our opinion, the immune-modulation, anti-inflammatory, and homeostatic properties of SVF within the joint through growth factors and cytokines, and not the ability of ASCs to regenerate cartilage ([@B20]; [@B27]). However, it would be interesting to better investigate whether ASCs injected within the joint may migrate to the cartilage lesions and promote healing and regeneration. Moreover, SVF is accessible and does not require cell separation or culturing conditions. Thus, the therapeutic cellular product is instantaneously obtained and has minimal contact with reagents resulting in a safer and more eligible option concerning regulatory standards. In the light of current knowledge, we hypothesize that the amount of ASCs obtained from the SVF is irrelevant to the mechanical procedure in clinical settings due to insufficient data and in relation to the minimum number of cells and the clinical improvement. In conclusion, investigations on adipose tissue-derived cell isolation systems have been conducted to ensure a safe and sterile isolation technique without contamination and unpredictability of cell material. Every method or system, clearly holds specific advantages and disadvantages in cost and handling. For these reasons, additional preclinical and clinical studies are required to support these preliminary findings.

Conclusion
==========

Mechanical techniques are effective in isolating SVF from adipose tissue with low differentiative capability but high immunomodulatory effect through cytokines and growth factors release. Mechanical methods are appealing because they are simple, quick and generally not associated with expensive equipment or disposables. While more expensive, enzymatic methods obtained more nucleated cells with a higher number of progenitor cells per volume of lipoaspirate processed with high ability of differentiation. Moreover, the FDA very clearly states that the isolation of SVF cells from adipose tissues, with or without the use of proteolytic enzymes, results in a final product which is considered to be "more than minimally manipulated" because the original structure of the adipose tissue has been significantly altered. All this is overtaken by mechanical systems that are capable of minimizing tissue manipulation. To date, the research must be oriented toward mechanical systems that are able to isolate CD34+ progenitor cells with the same capacity as the cells obtained from enzymatic digestion. To date, instead, the mechanical systems are able to provide a good cocktail of growth factors with an immunomodulatory activity for palliative-type clinical uses.
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